Medicare is now offering $50 GLP-1 prescriptions. The US may never be the same.

The latest breakthrough for GLP-1 drugs isn’t scientific. It’s financial.

As of July 1, Medicare is providing coverage of GLP-1 medications for weight loss for just a $50 co-pay, potentially enabling millions more Americans to get onto this much-hyped new class of drugs. Medicare’s GLP-1 Bridge Program, as it is called, is technically a one-year pilot project authorized by the Trump administration. Medicare previously limited GLP-1 coverage to people who have diabetes, heart disease, or obstructive sleep apnea.

Under the new program, Medicare enrollees will be eligible to receive one of three drugs, Foundayo (the new once-a-day tablet), Wegovy, or Zepbound, for weight loss specifically. Patients generally qualify if they have a body mass index of 35 or higher, or a BMI of 27 or higher with certain health conditions.

The new program could prove to be an inflection point for a class of drugs that has already generated so much excitement and interest. It is a story with enormous implications, not only for Americans’ health, but for the economy at large.

“We call [this drug] a physiological disruption akin to technological disruptions of our time like the smartphone. When the smartphone first came out, no one anticipated Uber or TikTok or Netflix streaming,” Alison Furman, partner and US consumer markets industry leader at PwC, said at Aspen Ideas: Health. “This is no different. You are going to see new brands, new products, new industries form around this ecosystem that this drug is already creating.”

The percentage of households with a GLP-1 user had already doubled from January 2025 to May 2026, per PwC. And that was before the launch of the Bridge program, which seems likely to act as an accelerant on several trends that are already underway.

A lot more Americans are about to start taking a GLP-1 drug

About 12 percent of Americans said in an August 2025 survey that they had taken a GLP-1 drug, equivalent to more than 40 million people. As of May 2026, one in five US households had at least one GLP-1 user, according to data from PwC, and those shares are probably as low as they will ever be.

Millions more are likely to join them with Medicare’s coverage broadening under the Bridge program.

Exactly how many remains to be seen. According to one KFF estimate of the Medicare population, as many as 14 million people on the program are obese or overweight. A more recent KFF estimate using the Bridge program’s specific qualifications concluded that about four million beneficiaries could be eligible for the $50-per-month GLP-1 offer.

Doctors are expecting an onslaught of new patients: As Axios reported in June, clinics are worried they may be overwhelmed by the increased demand that follows the Bridge program’s launch. It is expected to be one of the largest prescription drug rollouts ever.

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American healthcare policy. Sign up here.

And it’s not the end. Pharmaceutical executives say they are making inroads with the private employer-based insurance plans that cover about half of the US population; at Aspen Ideas: Health in late June, Laura Steele, group vice president of US cardiometabolic health at Eli Lilly, said the company has seen employer coverage increase significantly, from about 20 percent covering to 67 percent. Drug manufacturers have also gotten aggressive about selling prescriptions directly to the consumer at a reduced cash price, as have other DTC healthcare businesses like Hims and Hers.

Cost remains a barrier to uptake. According to a November 2025 KFF survey, more than half of GLP-1 users said the drugs were difficult to afford; 14 percent said they had stopped taking the weight-loss meds because of the cost. Even with millions of Americans already on a GLP-1, adoption could still grow exponentially as costs come down. About three-fourths of US adults are overweight or obese. Furman said that between 50 and 75 percent of Americans could be taking one of these medications in 10 years.

More widespread use could reduce the stigma around GLP-1 use

Millions more people going on GLP-1s could also alter one of the defining features of the recent weight-loss boom: the stigma that some people still experience for using one of these drugs.

The reality of such a stigma is undeniable. Reddit communities dedicated to these drugs and patients’ weight-loss journeys are filled with stories of people experiencing judgment or other negative reactions from people in their lives who find out they are taking a GLP-1. It’s not just anecdotal, either: One randomized experiment from researchers at Rice University found that people reported feeling more negative emotions when hearing that somebody lost weight using a GLP-1 drug compared to losing weight with diet or exercise, or not even losing weight at all.

But there are signs that stigma is starting to break down. According to PwC data shared with Vox, 23 percent of current GLP-1 users openly share that they are on the drugs, compared to the 2 percent who say they haven’t told anyone. And people who are considering going on a GLP-1, the kind of people who may now take the leap with the Medicare Bridge program, are even more open-minded. More than half of those considerers (53 percent) say they would share their use with their immediate family members, versus 42 percent of current users.

If the financial barriers were the No. 1 factor holding back GLP-1 adoption, stigma might have been the No. 2 reason. Now both of those are trending in the opposite direction: The drugs are becoming more affordable, and according to the data, the stigma around using these medicines may not be as stifling as it used to be.

As GLP-1 use expands, the economy will be permanently altered

And as GLP-1 use expands, the ripple effects already being felt in the US economy could turn into waves. A recent PwC consumer survey illustrates how dramatically people’s spending habits can change when they or somebody in their household goes on one of these weight-loss medicines.

More than half of GLP-1 users said they were spending less at the grocery store on sweet snacks (including candy and baked goods) and salty snacks; 43 percent said they said they were buying fewer sugary beverages, and 12 percent said they were buying less alcohol. At the same time, 45 percent reported purchasing more fresh produce, 35 percent bought more protein-packed snacks, and 28 percent said they spent more on high-fiber foods.

The restaurant industry is in for a shake-up too: Spending on pizza, for example, dropped 22 percent among GLP-1 households, which also spent less on takeout chicken (down 12 percent), coffee and bakery items (8 percent), burgers (6 percent), and deli sandwiches (4 percent).

“When people are eating less, they tend to favor quality over quantity,” Furman said.

And the GLP-1 effect is felt beyond food shopping or dining out: Users also spend 10 percent more on apparel (specifically women’s jeans, swimwear, dresses, and jewelry) within six to eight months of going on the medication.

These weight-loss meds could ultimately change parts of the economy that go beyond consumer spending. One recent study suggested that women who go on a GLP-1 have an easier time finding a job. (Although we should still be cautious about interpreting the results of a single study, as one economist pointed out.)

The point is, a massive weight-loss revolution that affects 50 percent of the US population or more is going to have huge consequences beyond a lot of people walking around looking slimmer. If current trends hold, we may eventually look back at the economy, and the United States as a whole, in pre- and post-GLP-1 terms.